Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1Myeloid 1Lymphoid 1Dermatologic 1

Conditions

Carcinoma, Transitional Cell 16Urinary Bladder Neoplasms 15Carcinoma, Merkel Cell 10Neoplasm Metastasis 8Carcinoma, Renal Cell 8Breast Neoplasms 8Neoplasms 6Triple Negative Breast Neoplasms 5Melanoma 5Ureteral Neoplasms 4Stomach Neoplasms 4Squamous Cell Carcinoma of Head and Neck 4Ovarian Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Uterine Cervical Neoplasms 3Urethral Neoplasms 3Skin Neoplasms 3Prostatic Neoplasms 3Colorectal Neoplasms 3Small Cell Lung Carcinoma 2Sarcoma 2Neuroendocrine Tumors 2Head and Neck Neoplasms 2Endometrial Neoplasms 2Carcinoma, Squamous Cell 2Carcinoma, Hepatocellular 2Uveal Melanoma 1Urothelial Cancer 1Turcot syndrome 1Thymoma 1

Interventions

Rituximab 52Cyclophosphamide 49Lenalidomide 40fludarabine 24obinutuzumab 22Prednisone 18Magnetic Resonance Spectroscopy 18Bendamustine Hydrochloride 18Vincristine 16fludarabine phosphate 15Specimen Handling 15Doxorubicin 15zanubrutinib 13Biopsy 12tazemetostat 10ibrutinib 10Whole-Body Irradiation 10pembrolizumab 9Peripheral Blood Stem Cell Transplantation 9venetoclax 8Mycophenolic Acid 7Etoposide 7axicabtagene ciloleucel 6Radiotherapy 6CT-P10 6Therapeutics 5R-CHOP protocol 5tisagenlecleucel 4tafasitamab 4polatuzumab vedotin 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma, Follicular × avelumab × 1 year × Clear all
NCT04328844 2026-03-30

A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers

iOnctura

Phase 1 Active not recruiting
210 enrolled
DermatologicLymphoidMyeloidOther solid neoplasmThoracic

Uveal Melanoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Melanoma, Mesothelioma, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡